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ABSTRACT 
Sjogren's syndrome (SS) is a chronic, multisystem inflammatory disorder of 
multifactorial etiology resulting in loss of secretory function in the exocrine glands 
including salivary and lacrimal. Even though the pathophysiology progression of SS has 
been subject to great amount of research, the roles of different mechanisms remain 
inconclusive. The main dogma is that immune system pathology drives SS; however, 
there is no straightforward pathogenesis theory as there are multiple autoantibodies and 
changing proportions of different T-cell subsets with the progression of the disease along 
with many other different contributors. Interestingly, increasing evidence points to 
structural defects, including defective E-cadherin adhesion, to be involved in the etiology 
of SS. Recently, the Hippo signaling pathway has emerged as one of the main pathways 
regulating size of the organs and proliferation/ differentiation of cells, in part via 
interaction with E-cadherin junctions. Despite this, the role of Hippo signaling in the 
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development and dysfunction of the submandibular gland (SMG) has not been 
investigated. 
Using ex vivo cultures of the embryonic mouse SMG, the present study shows that 
Hippo signaling is required for proper morphogenesis and organization of ductal 
structures. The Hippo signaling pathway is activated with morphogenesis, as shown by 
increased phosphorylation of a Hippo effector, TAZ, concomitant with its greater 
interaction with E-cadherin and a-catenin. Inhibition of a Hippo pathway kinase, Lats2, 
results in dysmorphogenesis of the SMG and impaired duct formation. SMGs from NOD 
mice, a mouse model for SS, phenocopy the Lats2-inhibited SMGs and exhibit 
pronounced reduction in E-cadherin junctional components, including TAZ. Importantly, 
we demonstrate that labial specimens from human SS patients exhibit mislocalization of 
T AZ from junctional regions to the nucleus, coincident with accumulation of 
extracellular matrix components, fibronectin and CTGF. Our studies show for the first 
time that Hippo signaling plays a role in SMG branching morphogenesis and provide 
evidence that defects in this pathway are associated with SS in humans. 
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Introduction 
Sjogren's syndrome (SS) is a complex chronic autoimmune disease of the exocrine 
glands, such as salivary and lacrimal, whose manifestations include hypo-salivation, 
which results in the "sicca complex", a combination of ocular dryness, keratoconjuctivitis 
sicca, and dry mouth, xerostomia. Additional disease manifestations may also be present, 
including dryness of the skin and mucosa} surfaces (1). The difficulties in finding a 
treatment for SS are due to a lack of comprehensive understanding of the etiology and 
pathophysiological progression of the syndrome (2). 
The central dogma in SS and autoimmunity, in general, has been that the T cell 
receptor determines target specificity and that immune system pathology is the sole 
explanation for disease. In addition, recent studies have produced evidence for the role of 
B cells in SS as these patients show a general reduction of their CD27 + memory B cell 
levels in peripheral blood, while an accumulation of these cells is observed in their 
salivary glands (3, 4). Many aspects of SS are shared with other systemic autoimmune 
rheumatic diseases, including a female preponderance (9: 1 female to male), distinctive 
HLA-DR3, B8, DQ2, and C4, familial clustering with other autoimmune conditions, and 
the existence of shared clinical features such as arthritis and Raynaud phenomenon (2, 3, 
4). Despite many areas of overlap between SS and systemic lupus erythematosus (SLE), 
differences exist between them including the autoantibody profiles. For example anti-
Ro/SSA and anti-La/SSB are not criteria for SLE but are detected in approximately 50 to 
70 % of SS patients (4). 
The central dogma in SS, however, is challenged by the fact that in diabetes and SS-
associated neuropathology, structural defects often exist prior to the onset of autoimmune 
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disease (4-8). Further, recent findings in mice suggest a direct role of the tissue itself in 
disease targeting (8, 9). One alternative proposal for autoimmunity is that developmental 
defects are a primary contributor to target selection. Indeed, in non-obese diabetic (NOD) 
mice, an animal model for SS and type 1 diabetes, regeneration of target organs with 
exogenous stem cells restored the normal morphology of both salivary submandibular 
glands (SMGs) and pancreatic islets and made them resistant to disease (9). Recent 
findings from patients with SS also indirectly support the premise that the immune 
system may not be the only culprit for salivary gland dysfunction. Some hypofunctional 
salivary glands from SS patients display acinar cell atrophy, loss of E-cadherin junctions, 
mislocalization of proteins, dilated ducts and remodeling of extracellular matrix (ECM), 
and the extent of such pathology does not always correspond to the level of lymphocytic 
filtrations (10-12). Furthermore, the degree of secretory defects does not always 
correspond with the extent of lymphocytic infiltration, suggesting that at least in some 
patients, defective secretion and autoimmunity are not linked (1, 13). Since little is 
known about the etiology of SS, it is of fundamental importance to identify the key 
molecular and cellular processes that either drive or contribute to the structural defects 
that are characteristic of SS tissues. In this context, identification of the molecular events 
that are essential for the development of the SMG and whose dysregulation gives rise to 
structural defects in NOD mice that mimic SS in humans is critical. 
Development of the SMG is regulated by instructive cues derived from the reciprocal 
cross talk between the epithelium and mesenchyme, as well as from interactions with the 
endothelium and the neuronal system (14, 15). During development, multiple signals are 
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integrated to regulate cell proliferation, apoptosis and cytodifferentiation in a proper 
spatiotemporal manner (16). To date, numerous studies have identified factors regulating 
SMG development, such as EGF and FGF growth factors and their receptors, components 
of the ECM and cytoskeletal regulators (17-21). Our earlier studies have shown that E-
cadherin, the primary salivary cell-cell adhesion receptor that organizes adherens 
junctions (AJs) in the SMG, is a key regulator of branching morphogenesis through its 
functions in ductal cell differentiation, ductal axis extension, proliferation of acinar and 
ductal progenitors and in the establishment of apical-basal polarity (22). 
Recent studies have unveiled a critical role for the Hippo signaling pathway in 
regulating cell fate, cell-polarity, ECM remodeling, tissue homeostasis and organ growth 
(23-26). In mammals, the primary downstream effectors of the Hippo pathway are the 
paralogous proteins T AZ and YAP. The functions of T AZ and YAP are determined by 
their localization, which is regulated by their phosphorylation. A kinase cascade, 
consisting of the MSTl/2 and Lats 1/2 kinases, promotes T AZ and YAP phosphorylation, 
which leads to their nuclear exclusion. Inhibition of the Hippo pathway kinases allows 
non-phosphorylated T AZ/YAP to shuttle to the nucleus, where they function as 
transcriptional regulators that promote proliferation and inhibit apoptosis (24, 27). 
Furthermore, E-cadherin-associated protein complexes are upstream regulators of the 
Hippo pathway, in part, through the association of T AZ/YAP with a-catenin (28, 29). 
Also, E-cadherin and its junctional component, a-catenin, have been shown to control 
cell proliferation via Hippo signaling (28-30). For instance, in sparse cells forming 
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nascent E-cadherin junctions, T AZ/YAP localize predominantly to the nucleus, while in 
dense cells with mature E-cadherin junctions, TAZ/Y AP are in the cytoplasm (31). 
NOD tissues, such as salivary glands and pancreatic islets, uniformly display lack of 
E-cadherin adhesion in situ and altered cellular adhesion in isolated cells (8). Since Hippo 
signaling has been shown to be required for cell polarity and differentiation, it was 
possible that defects in this pathway were the involved in NOD dysfunction and SS 
phenotype in humans. Although Hippo signaling is increasingly recognized to play key 
roles in tissue development and homeostasis, little is known about its involvement in the 
SMG branching morphogenesis. In this study, we use the mouse SMG ex vivo organ 
culture, a well-recognized model for studies of key regulators and molecular mechanisms 
underlying early branching morphogenesis, as an experimental system (15, 21, 22, 32). 
We examine the Hippo signaling pathway during SMG embryonic development and the 
pathological consequences of its defects by in-depth cell biological, biochemical and 
functional analyses. We then validate the involvement of dysregulated Hippo signaling in 
labial biopsies from human patients with SS. Collectively, our findings show that 
defective Hippo signaling contributes to the structural defects in the SMG and that it is a 
feature of SS in humans. 
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Materials and methods 
Mouse strains 
For the mouse studies, CD-1 wild type and NOD mouse strains were used. The CD-1 
mouse is a multipurpose model that can be used in such fields as toxicology (safety and 
efficacy testing), aging and oncology. This is principally due to efficient breeding and 
large litter sizes. NOD mice are used as an animal model for type 1 diabetes and SS. 
Typically, NOD mice develop SS in the postnatal period. CD-1 and NOD mice were 
obtained from the Boston Children's Hospital (Boston, MA). The mice were housed in 
barrier facilities on a 12Dh light/dark cycle. Food and water were supplied ad libitum. 
Mice were handled at the institute's animal facility, and all treatments were in accordance 
with the respective institutional guidelines. The day the vaginal plug was detected was 
considered embryonic day 0.5 (E 0.5). All animal experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Boston University Medical 
Center. 
Minor human salivary glands 
Formalin fixed, paraffin embedded lower lip minor salivary glands were collected 
with a written consensus from three different biobanks in Oslo, Norway. The Norwegian 
Committee of Ethics approved the use of the biopsies in the study. To assure proper 
diagnosis, an oral pathologist reevaluated all biopsies blindly using American-European 
Consensus Criteria (AECC) criteria to determine the focus score (the number of focal 
mononuclear cell infiltrates with ~50 mononuclear cells per 4 mm2). Minor salivary 
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glands evaluated for SS, but not fulfilling AECC criteria served as controls. Patients with 
SSA or SSB autoantibodies, or patients diagnosed with secondary SS, were excluded as 
controls. For each marker analyzed by immunostaining, a minimum of six biopsies from 
SS compatible patients and six non-compatible controls were used. 
SMG organ cultures 
SMG salivary gland rudiments were dissected from embryos at E13.5-E18.5, cultured 
on Whatman Nucleopore Track-etch filters (GE healthcare, Buckinghamshire, UK) and 
grown in an air/medium interface at 37°C in a humidified 5% CO2 atmosphere (24). The 
filters were placed on top of 200 µl media containing DMEM/F12 (ATCC, VA, USA) 
supplemented with 150 µg/ml vitamin C, 50 µg/ml transferrin, 100 µg/ml penicillin and 
100 µg streptomycin in 30 mm glass bottom microwell dishes (MatTek, MA, USA) with 
six glands per filter. During transfection with small interfering RNA, penicillin and 
streptomycin were omitted from the growth media. For functional studies using Lats2 
siRNA, glands were photographed at 0, 24 and 48 h using a Nikon Eclipse TS 100 
microscope (Nikon, Tokyo, Japan). For analyses of SMGs treated with Lats2 siRNA, 23 
silenced and 23 non-silenced glands were analyzed to measure the gland area and number 
of buds using ImageJ software (version 1.45s). 
Antibodies 
Antibodies to T AZ, E-cadherin, fibronectin, IQGAPl and ~-catenin and were 
purchased from BD Transduction Laboratories, CA, USA. Two antibodies to a-catenin, 
one produced in mouse and one produced in rabbit were obtained from Sigma, MO, USA 
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and BD Trandsduction Laboratories, respectively. The antibody to phospho-YAP, also 
recognizing phosho-TAZ, was obtained from Cell Signaling Technology, MA, USA. 
The antibody to YAP, also recognizing T AZ, was purchased from Santa Cruz 
Biotechnology, CA, USA. While these antibodies recognize both T AZ/YAP and 
pT AZ/p YAP, they easily distinguish between T AZ and YAP on immunoblots due to their 
different molecular weights of 50 kDa for T AZ and 75 kDa for YAP. Antibodies to 
connective tissue growth factor (Ctgf) and total YAP were purchased from Abeam, MA, 
USA. 
Immunofluorescence analyses 
Formalin fixed paraffin-embedded human labial salivary glands biopsies were cut into 
4-6 µm sections using a Lei ca serial Microtome (Lei ca Instruments, Solms, Germany) 
and placed on SuperFrost® Plus microscope slides (Thermo Scientific, MA, USA). 
Before staining, each slide was rinsed in distilled water prior to heat induced epitope 
retrieval in a microwave using 9: 1 Retrievit-6 Target Retrieval Solution (Biogenex, CA, 
USA) and MilliQ water. Slices were cooled for 20 min prior to overnight blocking in 10% 
goat serum (Sigma) at 4°C. Sections were incubated in primary antibodies diluted in 
PBS-T (20mM Tris, 137 mM NaCl, 0.1 % Tween 20, pH 7.6) with 10% BSA for 1 hat 
room temperature (RT). The slides were washed in PBS-T before incubating in goat anti-
mouse AlexaFlour® 594 (Invitrogen, NY, USA) or goat anti-mouse FITC tagged 
(Invitrogen) secondary antibodies diluted at 1: 100 in PBS-T, and counterstained for 
nuclei with DAPI (Invitrogen) at RT for 30 min. The slides were then washed 3 times in 
PBS-T before mounting using Vectashield (Vector Laboratories, CA, USA) and 
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Microscope Cover Glass (Fisher Scientific, MA, USA). For negative controls, the 
primary antibodies were omitted. 
For whole mount immunofluorescence of mouse SMGs, El3.5, E15.5 and El 8.5 
glands were grown on filters for 2 h prior to fixation in 3.7% paraformaldehyde for 40 
min at RT. The glands were then washed in PBS and permeabilized using 0.1 % Triton-X 
in PBS for 20 min (E13.5) or 40 min (El5.5 and E18.5) at RT. After permeabilization, 
the glands were washed 3 times in PBS-T prior to overnight blocking in 10% goat serum, 
10% BSA and PBS-Tat 4°C. Primary antibodies were diluted 1:100 in 10% BSA and 
PBS-T and incubated for 3.5h at RT. The glands were washed in PBS-T before adding 
FITC conjugated secondary antibodies (lnvitrogen) at 1: 100 dilution in PBS-T for 2h at 
RT. The secondary antibodies were removed, and Rhodamine Phallodin (lnvitrogen) at 
1: 100 and TO-PRO®-3 iodide (lnvitrogen) at 1: 1000 were added to the glands for an 
additional 30 min at RT. The glands were then washed overnight and mounted on 
SuperFrost®Plus microscope slides (Thermo Scientific) using 15 µl Vectashield (Vector 
Laboratories). The immunostained glands were then analyzed using a Zeiss LSM 510 
confocal microscope as previously described (22). 
Tissue extraction 
SMG glands were immediately frozen on dry ice following dissection and were kept at 
-80°C prior to protein extraction. For the preparation of total tissue lysates, SMGs were 
extracted in OGT buffer (10 mM imidazole, 3 mM sodium pyrophosphate, 100 mM NaCl, 
1 % Triton X, 5 mM EDTA, 1 mM MgC12, 45 mM n-Octyl ~-D glucopyranoside) 
8 
supplemented with a protease inhibitor cocktail (Sigma) and 100 mM PMSF. Whole 
tissue lysates were used for detection of selected proteins and protein complexes by 
immunoblot and immunoprecipitation. Protein concentration was determined using the 
BCA assay (Thermo Scientific). 
Immunoblot and co-immunopercipitation 
For biochemical analyses, 10-15 glands from El3.5, 6-8 glands from E15.5, or 2-4 
glands from E18.5 stages of embryonic development were collected from the same litter 
and kept on dry ice prior to protein extraction as described above. For each embryonic 
time point, 50 µg of protein was used with reducing 2x sample buffer (Sigma). The 
samples were heated at 95°C for 5 min before being fractionated on 7.5% SDS-PAGE. 
The gel was electrophoretically transferred onto PVDF membranes (Invitrogen) at 60V. 
The membrane was blocked for 1 h in 10% milk prior to overnight incubation in primary 
antibody at 4 °C, followed by 1 h incubation at 27°C using secondary horseradish 
peroxidase-conjugated antibodies (Sigma). ECL plus detection reagent (GE healthcare) 
was used for visualization of bands, and quantification analysis of band intensity was 
performed using ImageJ software (version 1.45s). 
For analyses of protein interactions by co-immunoprecipitation, 300 µg of total tissue 
lysate was prepared from either El5.5 or E18.5 glands. Unspecific binding to IgG was 
removed by pre-clearing with normal mouse IgG (Santa Cruz Biotechnology) for 1 h. 
Samples were incubated with primary antibody for 2 h followed by incubation with 
Protein Agarose Beads (GE Healthcare) for I has described previously (22, 33). 
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Immunoprecipitates were subjected to electrophoresis under either reducing or non-
reducing conditions, as described above. 
RNA interference 
Small interfering RNAs (siRNA) targeting Lats2 were obtained as SMART-pool™ 
sequences (Dharmacon, CO, USA) while the non-silencing negative control siRNA was 
from QIAGEN, Hiden, Germany. To determine optimal siRNA concentrations, different 
amounts ranging from 100 to 400 nM were tested for various time periods. The most 
distinct phenotype was observed using 400 nM siRNA at 48 h. From each mouse embryo, 
one gland was used for silencing while the corresponding gland was used as a non-
silencing control. Six glands were placed on each filter and transfected using RNAiFect 
(QIAGEN) with either 400nM of siRNA targeting Lats2 or a non-silencing, scrambled 
control. After transfection, glands were incubated at 37°C for 48 h and frozen in sterile 
tubes for protein or RNA extraction or fixed in 3.7% paraformaldehyde prior to 
immunostaining. 
RNA extraction and RT-PCR 
RNA from SMGs was extracted using the Qiagen RNeasy Minikit, and cDNA was 
prepared using SuperScript III (Invitrogen). Gene expression profiles were generated by 
normalizing the Ct (threshold cycle number) of Lats2 with housekeeping gene 18S and 
by comparing the gene expression of SMGs treated with silencing Lats2 siRNA (S) to 
non-silencing siRNA (NS). Statistical analysis was performed using an unpaired sample 
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t-test comparing mRNA expression levels of Lats2 in NS controls to Lats2 siRNA treated 
glands from three different RNA preparations. 
Statistics 
For immunoblot and co-immunoprecipitation assays, mean values from a minimum of 
triplicate samples are reported± SEM. All data were analyzed using unpaired sample t-
tests. Values of p<0.05 were considered significant. 
11 
Results 
Expression and localization of the Hippo pathway effector TAZ during SMG 
embryonic development 
Cytodifferentiation of the SMG requires the formation of mature E-cadherin junctions 
that play pivotal roles in diverse processes, including proliferation of ductal and acinar 
progenitors, survival of differentiating duct cells and establishment of apical-basal 
polarity in differentiated acinar and ductal cells (15, 22, 34, 35). Since Hippo signaling 
has been shown to play key roles in tissue development, and since activation of the Hippo 
pathway leads to phosphorylation of T AZ/YAP concomitant with their localization to E-
cadherin-containing cell-cell junctions and nuclear exclusion (24, 28), we sought to 
determine if Hippo signaling was involved in SMG development. As an experimental 
system, we used ex vivo organ cultures of the embryonic mouse SMG, known to 
recapitulate SMG development in vivo (Figure la) (15, 22). In particular, we have 
focused on the expression and localization of one Hippo effector, TAZ, at three 
embryonic stages representing early morphogenesis at El3.5, initial cytodifferentiation at 
E15.5 and late cytodifferentiation at E18.5. At these stages, E-cadherin junctions undergo 
dynamic changes in organization, with increasing levels of associated a-catenin 
indicating junction maturation (22). Also, it has been shown that transcripts of T AZ are 
detected at these embryonic stages of development 
(http://sgmap.nidcr.nih.gov/sgmap/sgexp.html). 
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To investigate changes in Hippo pathway activity during SMG embryonic 
development, we first determined protein levels of TAZ and its phosphorylated form. 
Immunoblot analyses showed that the abundance of T AZ increased with 
cytodifferentiation (Figure 1 b, *p<0.05). This was associated with a progressive increase 
in the levels of phospho-TAZ from E13.5 to El8.5 (Figure le, *p<0.05). Comparison of 
ratios of phospho-T AZ to total T AZ revealed increased levels of the phosphorylated 
species at later developmental stages (Figure ld). Thus, cytodifferentiation of SMGs was 
accompanied by increased Hippo signaling pathway activity, suggesting that it plays a 
role in the establishment and/or maintenance of acinar and ductal cell polarity. 
To further examine how the Hippo pathway impacted SMG morphogenesis, we 
followed the expression and localization of T AZ at different stages of embryonic 
development by immunofluorescence localization coupled with confocal microscopy. 
Early in morphogenesis at El3.5, the distribution of T AZ was predominantly cytoplasmic, 
with a fraction localized to the sites of new duct formation as marked by F-actin in the 
proximal bud regions (Figure le, El3.5 , arrows , insets). In addition, T AZ was detected in 
the mesenchyme surrounding the epithelial buds. At El5.5, TAZ was more prominently 
defined in the newly forming duct regions, where it co-localized with F-actin (Figure le, 
El5.5, arrows, insets). Interestingly, at this stage, TAZ was present in both the cytoplasm 
and nucleus (Figure 1 f, arrows, X-Y and orthogonal X-Z sections). Late in embryonic 
cytodifferentiation at El8.5 , TAZ was organized at the lateral junctions in acinar and 
ductal cells (Figure le, El8.5, arrows, insets). We note that a significant fraction of TAZ 
was localized to sites representing either the basal regions of the SMG epithelium and/or 
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the adjacent myoepithelial and mesenchymal compartments. Collectively, these data 
showed that SMG cytodifferentiation was associated with increased levels of 
phosphorylated and junctional T AZ, especially in duct forming regions. 
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Figure 1. Expression and localization of T AZ during submandibular gland (SMG) 
embryonic development. (a) Phase microscopy images of CD-1 mice epithelial buds (e) 
and surrounding mesenchyme (m) isolated from embryonic days E12.5-E18.5 during 
SMG branching morphogenesis. Size bar: 20 µm. (b) Immunoblot of T AZ SMG 
expression levels at E13.5, E15.5 and E18.5. Bar graph, Fold change in TAZ levels after 
normalization to GAPDH, *p<0.05. (c) Immunoblot of p-TAZ expression levels at E13.5, 
E15.5 and E18.5. Bar graph, Fold change in p-TAZ levels after normalization to GAPDH, 
*p<0.05. (d) Ratio of p-TAZ to total TAZ at E13.5, E15.5 and E18.5. (e) 
Immunofluorescence localization of SMG TAZ (green) at E13.5, E15.5 and E18.5, 
counterstained with F-actin (red). (f) Immunofluorescence localization of TAZ (green) at 
E15.5, counterstained with nuclei (blue). 
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T AZ interacts with E-cadherin junctional complexes in a development-dependent 
manner 
Hippo has been shown to be a cadherin-based signal, with TAZ and YAP interacting 
with E-cadherin and a-catenin (36-38). Since localization of T AZ to cell-cell borders 
increased with SMG cytodifferentiation, we investigated whether this reflected greater 
interactions of T AZ with E-cadherin and a-catenin. Co-immunoprecipitation studies 
revealed that TAZ was present in E-cadherin protein complexes at El5.5, and that its 
association with E-cadherin scaffolds increased at E18.5 (Figure 2a). This coincided with 
a more focused organization of E-cadherin at cell-cell-cell borders at E18.5, previously 
shown to indicate formation of mature AJs (Figure 2c, arrows, insets) (22, 33). Likewise, 
immunoprecipitation of T AZ protein complexes revealed that they contained more a-
catenin at E18.5 compared to E.15.5 (Figure 2b), which reflected increased recruitment of 
a-catenin to cell-cell borders (Figure 2d, arrows, insets). We have previously shown that 
increased presence of a-catenin at the membrane reflected its association with mature E-
cadherin junctions (22). Furthermore, immunofluorescence analysis of SMGs doubly 
stained for TAZ and a-catenin revealed increased colocalization from E15.5 to E18.5 
(Figure 2e, arrows, insets). Thus, as E-cadherin junctions matured, TAZ became more 
associated with its protein scaffolds, most likely via a-catenin, suggesting that TAZ may 
have a role in junction maturation during SMG morphogenesis. At the same time, it is 
possible that by associating with T AZ, E-cadherin junctions prevented its nuclear 
localization and restricted its transcriptional activity. 
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Figure 2. T AZ interacts with E-cadherin junctional complexes throughout development 
in CD-1 mice. (a) E-cadherins were immunoprecipitated from E15.5 and E18.5 SMG 
tissue lysates and their interaction with T AZ was assessed by immunoblot. Bar graph, 
Quantification of TAZ/E-cadherin levels. (b) TAZ was immunoprecipitated from E15.5 
and E18.5 SMG tissue lysates and its interaction with a-catenin was examined by 
immunoblot. Bar graph, Quantification of a-catenin/T AZ levels. ( c) lmmunofluorescence 
localization of E-cadherin at E.15.5 and E18.5. Size bar: 20 µm. (d) lmmunofluorescence 
localization of a-catenin at E.15.5 and E18.5. Size bar: 20 µm. (e) lmmunofluorescence 
colocalization of a-catenin (red) and TAZ (green) at El5.5 and E18.5. Size bar: 20 µm. 
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Inhibition of the Hippo pathway Lats2 kinase perturbs SMG branching 
morphogenesis 
Upon Hippo pathway activation, a cascade involving MSTI/2 and Latsl/2 kinases 
leads to phosphorylation and subsequent nuclear exclusion of TAZ and YAP. Inhibition 
of Hippo signaling allows non-phosphorylated T AZ and YAP to accumulate in the 
nucleus, where they function as transcriptional regulators of proliferation promoting and 
apoptosis inhibiting genes (27). To further assess the role of Hippo signaling in SMG 
development, we examined the consequences of partial inhibition of Lats2 kinase in 
E 13 .5 ex vivo organ cultures on branching morphogenesis. 
Treatment of E13.5 SMGs organ cultures with siRNA to Lats2 kinase for 48 h resulted 
in a 30% reduction in its transcript levels in silenced (S) glands compared to non-silenced 
(NS) controls (Figure 3a). This modest decrease in Lats2 mRNA levels coincided with 
distinct morphological changes that included a flattened central area in the main 
branching region, larger endbuds and diminished overall branching (Figure 3b ). Indeed, 
morphometric measurements revealed that partial inhibition of Lats2 kinase led to a 
significant increase in the tissue surface area and to a significant reduction in the number 
of buds (Figure 3c, **p<0.01). 
Our previous studies have demonstrated that proximal areas of terminal buds are sites 
of presumptive duct formation, and that F-actin demarks newly forming ductal structures 
(22). While the sites of new duct formation contained tight F-actin cables in NS buds, in 
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the Lats2 inhibited glands, some regions exhibited dispersed patterns of F-actin 
distribution in the proximal, branching regions (Figure 3d, arrows, F-actin, NS and S). 
Since F-actin has been shown to delineate early stages of duct formation, its expanded 
patterns of distribution in Lats2-inhibited glands suggested that in the absence of Hippo 
signaling, duct initiation occurred but that its extension did not proceed normally. 
Therefore, Hippo signaling is necessary for proper duct development during SMG 
branching morphogenesis. 
We have previously reported that during duct development, E-cadherin becomes well 
organized at the apical lateral surfaces of differentiating duct cells and serves as a 
survival signal (22). In the Lats2-silenced glands, E- cadherin displayed altered 
organization in the prospective duct regions (Figure 3d, arrows, E-cadherin NS and S). 
Likewise, while T AZ exhibited a well-defined and focused co-localization with F-actin at 
the apical domains of newly forming duct regions in NS glands, in Lats2-silenced glands 
its organization was irregular and spread out, although it still followed the patterns of F-
actin (Figure 3e, arrows, T AZ & F-actin, NS and S). These data showed that the Hippo 
pathway Lats2 kinase played a crucial role in SMG branching morphogenesis, being 
necessary for normal duct formation, and suggested that Lats2-mediated regulation of 
T AZ supported its non-nuclear role in this process. 
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Figure 3. Inhibition of Lats2 kinase perturbs SMG branching morphogenesis in CD-1 
mice. (a) Quantitative PCR of Lats2 transcript levels in non-silenced (NS) or Lats2 
silenced (S) glands. **p<0.01. (b) Phase microscopy images of NS and S SMGs 
transfected at stage E13.5 at Oh and 48h after Lats2 inhibition. (c) Morphometric analyses 
of the number of buds at 48h/0h (top) and area of buds at 48h/0h (bottom) of NS and S 
SMGs. **p<0.01. (d) Immunofluorescence localization of E-cadherin (green), 
counterstained with F-actin (red), in NS and S glands. Size bar: 20µm. ( e) 
Immunofluorescence localization of T AZ (green), counterstained with F-actin (red), in 
NS and S glands. Size bar: 20 µm. 
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Embryonic SMGs from NOD mice display dysmorphogenesis coupled with altered 
expression of T AZ and E-cadherin junctional components 
Sjogren's syndrome affects exocrine glands, primarily the salivary glands, leading to 
decreased salivary secretion. While autoantibody profiles including Rheumatoid factor 
(RF) and anti-nuclear (ANA) are associated with many cases of SS patients, a diagnosis 
of SS is often confirmed with a biopsy of salivary tissues and presence of lymphocytic 
infiltration (56). Given our observations linking the Hippo pathway to salivary gland 
development, we next investigated the expression of T AZ in non-obese diabetic (NOD) 
mice. The NOD mouse has been used as a model of SS, as the diseases in these mice 
show many similarities to the human disease in terms of immunology and structural 
defects in several organs and to develop SS-like disease (8, 39). Since Hippo signaling 
has been shown to be required for cell polarity and differentiation, it is possible the 
defects in this pathway play a role in NOD dysfunction and SS phenotype in humans. 
We first examined the gross morphology of SMGs from the NOD mice and compared 
them to SMGs from wild type, CD-1 mice. Already at E13.5, SMGs from NOD mice 
displayed a broader initial branching region, and at E14.5, they exhibited a significantly 
more flattened morphology with less branching than the wild type glands (Figure 4a). At 
E15.5, NOD SMGs had larger endbuds and they lacked the three-dimensional budding 
pattern typical of CD-1 glands. These altered morphological changes and growth 
characteristics were also evident at E18.5, with NOD glands displaying less compact 
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morphology and diminished branching (Figure 4a). Interestingly, the morphological 
features of NOD SM Gs resembled Lats2 silenced glands. 
Comparison of expression levels of E-cadherin junctional components in NOD SMGs 
showed dramatic changes in their abundance at all three stages of embryonic 
morphogenesis. E-cadherin levels decreased in NOD glands as development progressed 
(Figure 4b ). While levels of a-catenin, a key mechanosensor driving the interactions 
between E-cadherin junctions and F-actin, were higher in E13.5 NOD glands than in their 
wild type counterparts, they declined with cytodifferentiation at E15.5 and E18.5 (Figure 
4c). Interestingly, IQGAPl was more prominent in NOD SMGs at E18.5, suggesting that 
diminished E-cadherin adhesion was associated with increased expression of this junction 
destabilizer (Figure 4d)(40). The most dramatic changes in NOD SMGs, however, were 
detected for TAZ and its phosphorylated species, in particular. While at E13.5, levels of 
T AZ were similar between wild type and NOD SMGs, they were greatly diminished at 
later stages of cytodifferentiation in the NOD glands. This pattern was also observed for 
the phosphorylated form of TAZ, with dramatic reduction in phospho-T AZ in NOD 
glands already apparent at E13.5 (Figure 4e & f). Loss of phospho-T AZ early in 
morphogenesis correlated with the defective branching morphology of E13.5 NOD 
SMGs. These findings further support the notion that the expression and phosphorylation 
status of T AZ are important for proper morphogenesis and cytodifferentiation of the 
SMG. 
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Figure 4. NOD mouse SMGs display dysmorphogenesis and altered expression levels of 
TAZ and E-cadherin junctional components. (a) Phase microscopy images of SMGs 
isolated from NOD mice on embryonic days E13.5-E18.5 during SMG branching 
morphogenesis. Size bar: 20 µm. (b) lmmunoblots comparing E-cadherin expression 
levels in CD-1 and NOD SMGs at E13.5, E15.5 and E18.5. Bar graph, Fold change in E-
cadherin levels after normalization to GAPDH. (c) lmmunoblots assessing a-catenin 
expression levels in CD-1 and NOD SMGs at E13.5, E15.5 and E18.5. Bar graph, Fold 
change in a-catenin levels after normalization to GAPDH. ( d) lmmunoblots comparing 
IQGAPl expression levels in CD-1 and NOD SMGs at E13.5, E15.5 and E18.5. Bar 
graph, Fold change in IQGAPl levels after normalization to GAPDH. (e) Immunoblots 
comparing TAZ expression levels in CD-1 and NOD SMGs at E13.5, E15.5 and E18.5. 
Bar graph, Fold change in TAZ levels after normalization to GAPDH, *p<0.05. (f) 
Immunoblots comparing p-TAZ expression levels in CD-1 and NOD SMGs at El3.5, 
E15 .5 and E18.5. Bar graph, Fold change in p-TAZ levels after normalization to GAPDH, 
*p<0.05. 
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NOD SMGs exhibit defects in duct formation 
Because expression levels of E-cadherin and a-catenin were greatly diminished in 
embryonic NOD SMGs undergoing cytodifferentiation, it was not possible to assess the 
interactions between T AZ and E-cadherin junctions by co-immunoprecipitation. To gain 
insights into the quality of E-cadherin junctions in NOD SM Gs, we investigated E-
cadherin localization by indirect immunofluorescence at E15.5, an embryonic stage at 
which pronounced differences in the abundance of both E-cadherin and a-catenin were 
detected between wild type and NOD SMGs. 
Whereas E-cadherin displayed apical-lateral organization in columnar cells in the 
duct-forming region of wild type glands, in SMGs from NOD mice, its distribution at the 
apical-lateral domains was less focused, coincident with the loss of columnar morphology 
and expansion of ductal lumens. (Figure 5a, arrows, E-cadherin). Similar aberrant pattern 
of distribution was also found for F-actin in NOD SMGs (Figure 5a, arrows, F-actin). 
Likewise, while a fraction of T AZ was found at the apical domains of cells in the 
branching ductal region in wild type glands, its localization was more diffuse in NOD 
SMGs, which also correlated with disorganized and broader distribution of F-actin 
(Figure 5b, arrows, TAZ & F-actin). Specifically, although TAZ was detected in the 
newly forming duct regions in both NOD and wild type SMGs, in NOD glands, the 
proximal organization of F-actin cables into the bud was less extensive. 
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This coincided with expanded and not tightly organized F-actin staining in NOD 
glands compared to the CD-1 glands (Figure 5b, arrows, F-actin). Importantly, the 
organization of F-actin in NOD SMGs was similar to that in the Lats2-inhibited glands 
(Figure 3, d &e). The observations that both Lats2-inhibited and NOD SMGs displayed 
aberrant duct formation and defects in apical-basal polarity suggested that NOD 
phenotype was associated with dysregulation of the Hippo pathway activity and reduction 
in phospho-T AZ levels, in particular. 
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Figure 5. NOD SMGs have aberrant duct formation and disorganized E-cadherin and 
TAZ. (a) Immunofluorescence localization of E-cadherin (green) in CD-1 and NOD 
mouse SMGs at stage E15.5, counterstained with F-actin (red). Size bar: 20 µm. (b) 
Immunofluorescence localization comparing T AZ (green) in CD-1 and NOD mouse 
SMGs at stage E15.5, counterstained with F-actin (red). Size bar: 20 µm. 
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Deregulation of Hippo signaling, loss of cell polarity and ECM remodeling are 
f ea tu res of SS 
Our studies so far have established a role for Hippo signaling in SMG development 
and aligned its dysregulation with defects in branching morphogenesis resembling SS-
like dysfunction in the SMGs from NOD mice. Next, we examined if aberrant Hippo 
signaling was also associated with SS in humans. Therefore, we evaluated human labial 
biopsy specimens from patients with SS for E-cadherin and its junctional components, ~-
catenin and a-catenin, as well as for the Hippo effectors, T AZ and YAP, by 
immunofluorescence analyses and compared them to tissue specimens from SS non-
compatible (Non-SS) individuals. 
Hematoxylin and Eosin (H&E) staining of biopsies from SS patients demonstrated 
loss of secretory tissue and lymphocytic infiltration, whereas in non-SS specimens, the 
overall tissue architecture was preserved (Figure 6a). To ensure that lymphocytic 
infiltrates did not affect our analyses, we examined sections distal from the lymphocytic 
foci. lmmunofluorescence analyses of labial salivary glands from control Non-SS 
individuals for E-cadherin and its associated catenins confirmed well-organized E-
cadherin junctions in acinar and ductal epithelia (Figure 6b-d, arrows, insets, Non-SS). 
In contrast, salivary glands from SS patients showed disrupted distribution of E-cadherin 
(Figure 6b, arrow, SS). 
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Reduced E-cadherin adhesion in SS specimens was further confirmed by diminished 
immunofluorescence staining of~- and a-catenins at lateral borders compared to non-SS 
controls (Figures 6c, d, arrows). In SS tissues, both TAZ and YAP were lost from lateral 
cell borders and were instead localized to the basal regions that coincided with the nuclei 
(Figure 6e, f, respectively , arrows, SS). Concomitant with the loss of a-catenin from cell-
cell junctions , labial salivary glands from SS patients displayed elevated immunostaining 
ofIQGAPl, known to destabilize E-cadherin adhesion by competing with a-catenin for 
the binding to ~-catenin (Figure 6g, arrow)(40). This resembled the scenario in NOD 
SMGs, which displayed upregulation of IQGAPl (Fig. 4d, arrows, insets). These 
structural changes in E-cadherin junctions were associated with deregulation of the 
downstream effectors of Hippo, TAZ and YAP. Interestingly, nuclear redistribution of 
T AZ and YAP in SS specimens correlated with stronger immunostaining of Ctgf, a 
downstream transcriptional target of T AZ and YAP (Figure 6h), and a known regulator of 
ECM-remodeling and inducer of fibrosis (41). Moreover, SS patient biopsies exhibited 
increased deposition of fibronectin, confirming ECM remodeling in these tissues (Figure 
6i, arrows). 
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Figure 6. Sjogren's syndrome (SS) compatible labial gland biopsies display loss of 
polarity, dysregulated Hippo signaling and ECM remodeling. (a) Hematoxylin and Eosin 
staining of a biopsy from an SS patient compared to an SS non-compatible (Non-SS) 
patient specimen. Size bar: 50 µm. (b) Immunofluorescence localization of E-cadherin in 
SS and Non-SS glands, counterstained with DAPI. Size bar: 20 µm. (c) 
Immunofluorescence analyses of a-catenin in SS and Non-SS glands, counterstained with 
DAPI. Size bar: 20 µm. (d) Immunofluorescence localization of a-catenin in SS and Non-
SS glands, counterstained with F-actin. Size bar: 20 µm. ( e) lmmunofluorescence 
localization of TAZ in SS and Non-SS glands (left panel), counterstained with DAPI 
(right panel). Size bar: 20 µm. (f) Immunofluorescence localization of YAP in SS and 
Non-SS glands (left panel), counterstained with DAPI (right panel). (g) 
Immunofluorescence localization of IQGAPI in SS and Non-SS glands, counterstained 
with DAPI. Size bar: 20 µm. (h) Immunofluorescence localization of CTGF in SS and 
Non-SS glands. Size bar: 20 µm. (i) lmmunofluorescence localization of fibronectin in 
SS and Non-SS glands. Size bar: 20 µm. 
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Discussion 
Results presented here show that the Hippo signaling pathway plays important roles in 
the SMG branching morphogenesis by impacting the organization of ductal structures. In 
addition, we provide evidence that dysregulation of Hippo signaling not only affects 
normal SMG development , but is also a feature of SMGs from NOD mice and of labial 
specimens from human SS patients . Collectively , these studies suggest that defects in 
Hippo signaling are associated with this disease. 
During SMG embryonic development, a fraction of a Hippo pathway effector, T AZ, 
changed from being diffuse in the cytoplasm to a more focused organization at 
intercellular junctions. An intercellular role of TAZ in SMG development is also 
supported by an increase in the expression of the phosphorylated form of T AZ during 
embryonic branching morphogenesis. Moreover, co-localization of TAZ with F-actin in 
duct forming regions was observed early in cytodifferentiation, and it was followed by a 
progressive increase in interaction of TAZ with E-cadherin and a-catenin, suggesting that 
by associating with these junctions , T AZ participated in defining future duct cells. In 
addition, at E15.5, a fraction of TAZ was nuclear, supporting its other role as a 
transcriptional co-activator of genes involved in remodeling the ECM at this stage of 
SMG cytodifferentiation (41). We also note that a pool of TAZ was localized to the basal 
layer and the surrounding mesenchymal/myoepithelial regions, suggesting an unexplored 
non-junctional and non-nuclear role for T AZ during SMG development. 
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E-cadherin plays a pivotal role in the development of mature junctions and in the 
establishment of cell polarity in epithelial tissues. Another Hippo effector, YAP, a 
paralog of T AZ, has been shown to bind to a-catenin, which mediates its cytoplasmic 
localization (28, 30). Also, the binding to E-cadherin has been shown to regulate cellular 
localization of YAP (29). Here, we show that similar to YAP, TAZ is associated with a-
catenin and with E-cadherin complexes, suggesting junctional regulation of its 
subcellular localization. Our previous studies have documented increased interactions 
between a-catenin and E-cadherin with SMG cytodifferentiation (22). These collective 
findings suggest that interactions between T AZ and E cadherin complexes in the SMG 
are mediated by a-catenin. It is also possible that a fraction of a-catenin associates with 
T AZ independently of E-cadherin. Moreover, since T AZ/E-cadherin and T AZ/a-catenin 
complexes increase with cytodifferentiation, it is likely that they are required for normal 
SMG development. Consistent with this interpretation, knockdown of Lats2 led to defects 
in branching morphogenesis and tissue size. Lats2 siRNA-treated glands also exhibited 
defects in ductal structures in terminal bud regions, suggesting a role for Hippo signaling 
in duct formation. These findings resemble studies demonstrating the importance of T AZ 
in normal alveolarization of lungs in mice ( 42). 
Earlier studies provided support for the role of developmental biology in the onset of 
autoimmunity in NOD mice, as normally developed SMGs from NODs evade 
autoimmune exocrinopathy (43). Also, studies with NOD salivary glands have shown 
that structural defects can occur independent of lymphocytic infiltration (8). Moreover, 
despite the fact that inflammation precedes hypo-salivation in NODs, there is only a weak 
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association between the progression of lymphocytic infiltration and reduction in salivary 
flow rate (8, 44). Nonetheless, only a few studies have focused on the relationship 
between structural defects acquired during development and autoimmunity in the etiology 
of SS (8, 43). Indeed, our studies show that NOD embryonic SMGs display similar 
features as the Lats2 siRNA-treated, or Hippo-inhibited, glands. For both NOD and 
Lats2-silenced glands, morphological alterations in the budding pattern , bud size and 
three-dimensional growth were evident. Moreover, SMGs from both NOD and Lats2-
silenced glands had alterations in duct formation. Interestingly, we observed marked 
decreases in expression levels of T AZ and its phosphorylated form in NOD SM Gs. This 
suggests that deregulation of the Hippo pathway may contribute to the changes observed 
in NOD SMG morphology, and may be one of the mechanisms driving structural 
alterations in these glands. 
Cumulative studies to date point to an intimate relationship between Hippo signaling 
and cell polarity (45). Our studies also show that human labial SS tissues exhibit 
structural defects in the acini with loss of E-cadherin and its associated components. This 
is consistent with the loss of E-cadherin and altered cell polarity reported in other SS 
studies (10, 46-48). Thus, altered cell polarity in SS may impact Hippo signaling that will 
ultimately affect downstream transcriptional events. Alternatively, defects in Hippo 
signaling may cause aberrant localization of T AZ to the nucleus and drive changes in 
transcription leading to extracellular matrix remodeling. Since T AZ functions as a 
transcriptional co-activator of CTGF , a key factor contributing to tissue fibrosis, 
regulation of its subcellular localization is likely to play an important role in SS. 
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Interestingly, our SMG development data also suggest that proper regulation of the Hippo 
pathway is important for maintaining accurate cell adhesion and polarity during SMG 
branching morphogenesis. Thus, altered cell polarity in SS may result from deregulation 
of the Hippo pathway. Further studies are needed to elucidate the precise mechanisms of 
how Hippo signaling collaborates with E-cadherin junctions and ECM components and 
how their defects contribute to the development of SS in humans. 
When examining patients with different degrees of inflammation, we found tissue 
integrity among the biopsies to be largely heterogeneous, with structural defects evident 
in regions of the glands not adjacent to infiltrates. Although structural defects and loss of 
polarity in some SS cases have been linked to hypo-secretion, their roles in increased 
susceptibility to lymphocytic infiltrations have not been explored. Interestingly, ablation 
of E-cadherin junction protein, a-catenin, has been shown to drive lymphocytic 
infiltration both in a mouse model and in a variety of cancers ( 49-51). Further studies are 
needed to determine how structural defects and loss of polarity may lead to increased 
susceptibility to autoimmune reaction. 
To date, the etiology of SS remains controversial, and a common etiopathogenic 
model involves genetic predispositions triggered by environmental, pathological and 
immunological factors that drive clinical manifestation, where loss of secretory function 
is believed to result from cytotoxicity caused by progressive lymphocytic infiltration (52). 
However, this model fails to explain why some hypo-functional glands display acinar cell 
atrophy, loss of intercellular junctions, mislocalization of proteins, dilated ducts and 
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remodeling of ECM, which do not necessarily correspond to the extent of lymphocytic 
filtrations (10, 12). Further, the degree of secretory defects does not always reflect the 
proportion of lymphocytic infiltration, suggesting that at least in some patients, defective 
secretion and autoimmunity are not linked (13). Here, we provide one possible molecular 
explanation for at least a subset of SS cases by demonstrating that the Hippo signaling 
pathway is important for normal SMG development and that its disruption leads to gross 
morphological changes of the SMG. Hippo inhibited glands resemble SMGs from the 
NOD mouse model of SS and some of their key features are also found in labial salivary 
gland specimens from human patients with SS. Thus, our studies show for the first time 
that a subset of SS cases is associated with dysregulation of the Hippo pathway and 
suggest a role for Hippo signaling in this disease. 
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